Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1160]

Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective

Dr Ricky Frazer and Dr Rebecca Dobson

Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective ( Dr Ricky Frazer and Dr Rebecca Dobson )

(Bio) Markers and milestones at the crossroads of mHSPC care 

Dr Miguel Ramírez-Backhaus, Prof Jozefina Casuscelli, Prof Gerhardt Attard

(Bio) Markers and milestones at the crossroads of mHSPC care  ( Dr Miguel Ramírez-Backhaus, Prof Jozefina Casuscelli, Prof Gerhardt Attard )

Challenging the status quo: Unlocking new horizons for patients with HR-NMIBC...

Prof Bernardo Hererra Imbroda and Dr Géraldine Pignot

Challenging the status quo: Unlocking new horizons for patients with HR-NMIBC after BCG treatment ( Prof Bernardo Hererra Imbroda and Dr Géraldine Pignot )

ASCO 2025: Importance of early testing in metastatic prostate cancer

Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida...

ASCO 2025: Importance of early testing in metastatic prostate cancer ( Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano )

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC

Dr David Braun - Yale School of Medicine, New Haven, USA

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC ( Dr David Braun - Yale School of Medicine, New Haven, USA )

Tumour microenvironment and circulating biomarkers predict response to...

Dr David Braun - Yale School of Medicine, New Haven, USA

Tumour microenvironment and circulating biomarkers predict response to immunotherapy in advanced RCC ( Dr David Braun - Yale School of Medicine, New Haven, USA )

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial...

Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer ( Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy )

ASCO 2025: Latest updates in mRCC

Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier...

ASCO 2025: Latest updates in mRCC ( Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier Puente )

Nivolumab plus ipilimumab vs gemcitabine-carboplatin in cisplatin-ineligible...

Dr Michiel Simon van der Heijden - Netherlands Cancer Institute, Amsterdam...

Nivolumab plus ipilimumab vs gemcitabine-carboplatin in cisplatin-ineligible metastatic urothelial carcinoma ( Dr Michiel Simon van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

New MOAs in prostate cancer treatment - what’s next?

Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini

New MOAs in prostate cancer treatment - what’s next? ( Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini )

QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC

Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA

QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC ( Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer